EcoDrugPlus

Dopamine Receptor D2

Ensembl ID : ENSPKIG00000005142
Gene Symbol: DRD2
3 Cross references
207 Possible Orthologues:

Dopamine Receptor D3

Ensembl ID : ENSPKIG00000013157
Gene Symbol: DRD3
1 Cross references
206 Possible Orthologues:

Dopamine Receptor D4

Ensembl ID : ENSPKIG00000014609
Gene Symbol: DRD4
3 Cross references
244 Possible Orthologues:

Dopamine Receptor D4

Ensembl ID : ENSPKIG00000002751
Gene Symbol: DRD4
4 Cross references
244 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSPKIG00000018395
Gene Symbol: LOC111860367
3 Cross references
212 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSPKIG00000024612
Gene Symbol: ENPP2
3 Cross references
227 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSPKIG00000019314
Gene Symbol: ENPP2
3 Cross references
19 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSPKIG00000008734
Gene Symbol: EGLN1
3 Cross references
158 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSPKIG00000023572
Gene Symbol: EGLN1
3 Cross references
217 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSPKIG00000002331
Gene Symbol: EGLN3
3 Cross references
201 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSPKIG00000021883
Gene Symbol: EPAS1
3 Cross references
212 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSPKIG00000010988
Gene Symbol: ECE1
1 Cross references
230 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).